1. B
R
E
A
BREAST CANCER IS AN UNCONTROLLED S
GROWTH OF BREAST CELL T
MAINLY TWO TYPES C
 DUCTAL CANCER (85-90%) A
 LOBULAR CANCER ( almost 8%) N
C
MOST FREQUENT CANCER AMONG WOMEN AND 2nd E
RANK IN WORLD
R

2. B
Breast profile:
R
A Ducts
B Lobules
E
C Dilated section of duct A
to hold milk
D Nipple S
E Fat
F Pectoralis major T
muscle
G Chest wall/rib cage
Enlargement C
A Normal duct cells
B Basement membrane A
N
C Lumen (center of duct)
C
E
R

3. RISK FACTOR- B
R
• AGE E
BEYOND • FAMILY HISTORY A
• MEDICAL HISTORY
CONTROL S
T
• WEIGHT
• PHYSICAL ACTIVITY C
IN CONTROL • ALCOHOL A
CONSUMPTION
N
C
E
INCIDENCE INCREASED WITH AGE R

4. E
TURNIN B
G
REDNES
S OR INWAR SWELLI R
NG OF
THICKNI D
ALL OR E
NG OF
THE
PART OF
BREAST
A
NIPPLE
SYMPTOMES
S
T
LUMP IN SKIN
THE IRRITATION
UNDERAR
M AREA
OR
DIMPLING
C
BREAST
PAIN A
NIPPLE N
PAIN
C
E
EARLY BREST CANCER MAY NOT HAVE SYMPTOMS
R

5. B
R
E
A
S
T
C
A
N
C
OPTIONS:Treatment choices for the person with cancer depend
on the stage of the tumor, that is, if it has spread and how far
E
R

6.  PARP - [poly (ADP-ribose) polymer] inhibitor B
R
E
It is a group of pharmacological inhibitor of the enzyme PARP
A
OLAPARIB M.O.A S
 it is a chemotherrapeutic agent T
 kills cells that divides rapidly
 Patient with BRCA 1 and BRCA 2 mutation are also In risk of devloping C
breast cancer
A
 they are often resistance other form of breast cancer treatment
N
 so it increases the reliance on PARP torepair their DNA. C
 so the PARP inhibitor significantly benefits in patient whose cancers are E
Susceptible to treatment.
R

7. B
R
E
FATIQUE A
SOMNOLENCE S
NEUSEA T
LOSS OF APPETIDE
THROMBOCYTOPENIA
C
A
N
C
E
R

8. B
R
E
Condition Intervantion Phase A
S
Metastatic Breast
Cancer
Drug: Lapatinib
Biological:Trastuzumab
Phase III (GSK) T
Breast cancer Drug:carboplatin Phase III (university of C
Drug:Docetaxel california, los angeles)
Biological: Trastuzumab A
N
C
E
R

9. B
R
condition intervantion phase E
Ovarian Cancer Drug: cediranib Phase I (Dana farber A
cancer institute)
S
Breast Cancer Drug: olaparib Phase II(Dana farber
cancer institute
T
-------------- ( GSK)
Breast cancer Drug:Anti-erbB2 C
A
N
C
E
R